AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects